Biologic Drug Analytics

Biosimilar Program Support

Biosimilar Program Support

For 20 years, ProtaGene has successfully supported pharma clients in developing over 25 different biosimilar molecules.

The quality requirements are critical for the development of biosimilars. These requirements are needed to generate evidence demonstrating the similar nature concerning the biosimilar product’s quality, safety, and efficacy to the innovator product.

Our biosimilarity programs evaluate structure and physiochemical properties, biological safety, purity, impurities, and stability. ProtaGene is highly experienced in performing comparability studies and in the analysis of biosimilar products in accordance with ICH Q6B and CHMP guidelines, including:

  • bullet Created with Sketch.

    Sourcing commercial product

  • bullet Created with Sketch.

    Establishment of QTPPs/CQAs

  • bullet Created with Sketch.

    QTPP driven biosimilar development

  • bullet Created with Sketch.

    Product characterization under development

  • bullet Created with Sketch.

    Product similarity and impurity comparability program design and management

  • bullet Created with Sketch.

    EU release testing

Featured Article

ProtaGene Weighs in on the Future of the Biosimilars Market

History repeats itself, and all indications are that biosimilars are, in meaningful ways, following a similar path to small-molecule generics. Many in the biopharmaceutical realm would likely dispute the comparison as biologics are considerably more complex, and demonstrating comparability is quite challenging. Read More →

Read Article

Analytical Solutions from Research to Market

Group Created with Sketch.
Research
Preclinical
Group 2 Created with Sketch.

Discovery – Pre-clinical

Biologic Candidate Evaluation, Optimization and Selection into IND

Group 3 Created with Sketch.
Phase I
Phase II
Phase III
Group 4 Created with Sketch.

Phase I – Phase III

Release, Clinical Data and Characterization Packages for Accelerating Phase I-III Programs through BLA

Group Created with Sketch.
Registration
Market
Group 2 Created with Sketch.

Registration – Market

Commercial-Stage Comparability Testing by Qualified Advanced Methods

Biologic Therapeutics Platform Expertise

Our deep experience advancing a diverse range of therapeutic platforms from research through market help the ProtaGene team design highly effective analytical programs that de-risk development and accelerate timelines to your next key milestones. Key biologic development areas include:

  • bullet Created with Sketch.

    Recombinant proteins—including complex, highly glycosylated proteins

  • bullet Created with Sketch.

    Multi-subunit complexes—protein, nucleotide, ligand

  • bullet Created with Sketch.

    mAbs

  • bullet Created with Sketch.

    ADCs and protein conjugates

  • bullet Created with Sketch.

    PEGylated proteins

  • bullet Created with Sketch.

    Bispecifics/multispecifics

  • bullet Created with Sketch.

    Fusion proteins

  • bullet Created with Sketch.

    Enzyme replacement therapies

  • bullet Created with Sketch.

    Biosimilars

  • bullet Created with Sketch.

    Vaccines, including subunit/recombinant

hero-animation

Analytical Systems

Enabled by state-of-the-art technology, ProtaGene offers an extensive range of analytical capabilities to support your biotherapeutic or gene & cell therapy projects.

See Systems List
hero-animation

Subscribe to Our Email List

Consent

Talk to Our Experts

Discover how ProtaGene can support your development programs

Contact Us